An observational study in Therapeutic Drug Monitoring and Critical Illness, sponsored by Universitätsklinikum Hamburg-Eppendorf. Completed at 1 site in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-11-08.
Sponsored by Universitätsklinikum Hamburg-Eppendorf · Observational
The posaconazole pharmacokinetic in critically ill patients will be studied in a prospective, non-interventional, monocentric observational trial.
The posaconazole pharmacokinetic in critically ill patients will be studied in a prospective, non-interventional, monocentric observational trial. Plasma specimens will be retrieved on consecutive days (max. 7 days) in order to measure posaconazole levels during the treatment episode.
1,881 studies on the registry are indexed under Critical Illness; 462 are open to participants now.
This study's enrollment of 10 is below the median of 130 across 867 observational studies indexed under Critical Illness.
Browse Critical Illness studies →Universitätsklinikum Hamburg-Eppendorf is the lead sponsor of 403 studies on the registry; 83 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Critically ill patients treated with posaconazole intravenously.
Exclusion Criteria:
Therapeutic Drug Monitoring of posaconzole is performed by measuring posaconazole concentrations in serum
Other: Posaconazole Therapeutic Drug Monitoring
Therapeutic Drug Monitoring is performed by measuring posaconazole concentrations in serum on seven consecutive days (anticipated).
Posaconazole Drug Exposure
Measurement of posaconazole concentration in serum
Time frame: seven days from therapystart
population-pharmacokinetic analysis 1
Analysis of Peak Plasma Concentration (Cmax) for posaconazole in the given cohort.
Time frame: 12 months after close out
population-pharmacokinetic analysis 2
Analysis of Area under the plasma concentration versus time curve (AUC) for posaconazole in the given cohort.
Time frame: 12 months after close out
Evaluation of probability of target attainment of posaconazole
Analysis of Monte-Carlo-Simulations in order to asses novel dosing regimens for posaconazole.
Time frame: 12 months after close out
Plan to share: No
No publications or documents are linked to this record.
This study is completed, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Universitätsklinikum Hamburg-Eppendorf